Kymera Therapeutics Presents New Preclinical Data for KT-579
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the presentation of new preclinical data for KT-579, a first-in-class, oral IRF5 degrader, at the American College of Rheumatology Annual Meeting.
KT-579 demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies.
- Kymera Therapeutics expects to begin Phase 1 testing for KT-579 in early 2026.
Kymera Therapeutics advances a new class of oral small molecule degrader medicines for immunological diseases.
Author's summary: Kymera Therapeutics presents new preclinical data for KT-579.
More News
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- 2 US Navy aircraft crash in South China Sea
- Weather forecast for this week in Frome - 27 Oct to 2 Nov
- Disparities in PsA Burden and Treatment Linked to Geographic and Social Factors
- CRC Screening Improvements Decrease Mortality, but Disparities Persist
- Deadline is Dec. 31 to apply for Renew NC grants - Hendersonville Lightning
- Meet the Next Generation of Physician Leaders at Rutgers Health
- Canada’s Lululemon Partners With National Football League
- Elon Musk could step down if Tesla pay plan is rejected